World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
31341
World Ranking
11298
National Ranking
5798

Overview

Mario E. Lacouture is affiliated with Memorial Sloan Kettering Cancer Center in the United States and specializes in the field of medicine, with a focused expertise in oncology and dermatology. Their research portfolio comprises 435 publications in medicine, including 140 specifically in oncology and 85 in dermatology. Additional subfields of their work include molecular biology, epidemiology, and immunology.

The main topics addressed in Lacouture's research include chemotherapy-related skin toxicity, colorectal cancer treatments and studies, and cancer immunotherapy and biomarkers. Other notable research areas are nonmelanoma skin cancer studies, hair growth and disorders, cancer treatment and pharmacology, and autoimmune bullous skin diseases.

Frequent coauthors in Lacouture's publications include Alina Markova, Stephen W. Dusza, Lukas Kraehenbuehl, Donald Y.M. Leung, and Veronica Rotemberg. These collaborations contribute to a broad and interdisciplinary approach within their research scope.

Mario E. Lacouture has published extensively in multiple research venues. Some venues with the highest number of publications include the Journal of the American Academy of Dermatology with 30 publications, the Journal of Clinical Oncology with 29, Diabetes with 9, Circulation with 8, and Annals of Oncology with 7.

Recent notable papers authored or coauthored by Lacouture include:

  • Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines, 2020, Annals of Oncology
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events, 2021, Journal for ImmunoTherapy of Cancer
  • Immune checkpoint inhibitor-related dermatologic adverse events, 2020, Journal of the American Academy of Dermatology
  • Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features, 2020, Journal of the American Academy of Dermatology
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors, 2020, Nature Cancer

Best Publications

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

    J. Naidoo;D. B. Page;B. T. Li;L. C. Connell

  • Mechanisms of cutaneous toxicities to EGFR inhibitors.

    Mario E. Lacouture

  • Management of Immunotherapy-Related Toxicities, Version 1.2019.

    John A. Thompson;Bryan J. Schneider;Julie Brahmer;Stephanie Andrews

  • Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

    Mario E. Lacouture;Edith P. Mitchell;Bilal Piperdi;Madhavan V. Pillai

  • Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Julie R. Brahmer;Hamzah Abu-Sbeih;Paolo Antonio Ascierto;Jill Brufsky

  • Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

    Mario E. Lacouture;Milan J. Anadkat;René-Jean Bensadoun;Jane Bryce

  • Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management

    Thomas J. Lynch;Ed S. Kim;Beth Eaby;Jody Garey

  • Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

    Eli L. Diamond;Benjamin H. Durham;Julien Haroche;Zhan Yao

  • Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

    Mario E. Lacouture;Shenhong Wu;Caroline Robert;Michael B. Atkins

  • Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

    V.R. Belum;B. Benhuri;B. Benhuri;M.A. Postow;M.A. Postow;M.D. Hellmann;M.D. Hellmann

  • Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

    Alice P. Chen;Ann Setser;Milan J. Anadkat;Jonathan Cotliar

  • Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study

    Eli L. Diamond;Eli L. Diamond;Vivek Subbiah;A. Craig Lockhart;Jean Yves Blay

  • Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

    E. Tiacci;J. H. Park;L. De Carolis;S. S. Chung

  • First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Ryan J. Sullivan;Jeffrey R. Infante;Filip Janku;Deborah Jean Lee Wong

  • Immune checkpoint inhibitor–related dermatologic adverse events

    Amaris N. Geisler;Gregory S. Phillips;Dulce M. Barrios;Jennifer Wu

  • Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

    Mario Lacouture;Vincent Sibaud

  • Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

    M. E. Lacouture;L. M. Reilly;P. Gerami;J. Guitart

  • Efficacy of MEK inhibition in patients with histiocytic neoplasms

    Eli L. Diamond;Benjamin H. Durham;Gary A. Ulaner;Esther Drill

  • Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

    Fernando Costa Santini;Hira Rizvi;Andrew J. Plodkowski;Andy Ni

Frequent Co-Authors

Klaus J. Busam
Klaus J. Busam Memorial Sloan Kettering Cancer Center
David M. Hyman
David M. Hyman Memorial Sloan Kettering Cancer Center
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center
Omar Abdel-Wahab
Omar Abdel-Wahab Memorial Sloan Kettering Cancer Center
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Alfred W. Rademaker
Alfred W. Rademaker Northwestern University
Neal Rosen
Neal Rosen Memorial Sloan Kettering Cancer Center
Paul B. Chapman
Paul B. Chapman Memorial Sloan Kettering Cancer Center
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to diverse online degree options and healthcare career paths. Many students look for specialized programs that fit their aspirations and busy schedules.

For those interested in mental health, psych np programs provide advanced training for nurse practitioners focused on psychiatric care, typically offered in flexible online formats.

If affordability matters, you’ll find the cheapest online health science degree options help start a healthcare career without heavy debt. For leadership roles, the cheapest online master degree in healthcare administration equips graduates to manage teams or facilities.

Registered nurses aiming for the highest qualifications may consider the cheapest online bsn to dnp programs. These programs lead to a Doctor of Nursing Practice, unlocking clinical and executive positions.

Online programs offer flexibility and cost savings, making it easier to pursue healthcare and medical careers suited to your interests and financial goals.

Best Scientists Citing Mario E. Lacouture

Trending Scientists